March 2023 tender notification
Pharmac is pleased to provide the latest tender results
Download the tender notification [PDF 71 KB]
Tender results
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2022/23 Invitation to Tender, dated 31 October 2022.
Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. Pharmac will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on 12 April 2023 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).
Pharmac cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2022/23 Tender – Principal Supply Status applies until 30 June 2026
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows:
1. Tenders awarded to currently listed Pharmaceuticals where no other brand is listed
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
Date of subsidy change |
Principal Supply date |
|---|---|---|---|---|---|---|
|
Naltrexone hydrochloride1 |
Tab 50 mg; 30 tablet blister pack |
$133.33 |
$83.33 |
Naltraccord (Teva) |
1 July 2023 |
1 December 2023 |
|
1This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 4 clause 2.3(c)(ii) of the 2022/23 Invitation To Tender. |
||||||
2. Tenders awarded to pharmaceuticals where at least one other brand is listed
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Entecavir |
Tab 0.5 mg; 30 tablet blister pack |
$52.00 |
$12.04 |
Entecavir (Rex) (Rex Medical) |
1 October 2023 |
1 March 2024 |
Entecavir Sandoz (Sandoz) Entecavir Mylan (Viatris) |
|
Ezetimibe |
Tab 10 mg; 30 tablet bottle pack |
$1.95 |
$1.76 |
Ezetimibe Sandoz (Sandoz) |
1 July 2023 |
1 December 2023 |
Ezetimibe Sandoz (Sandoz) Pharmacode 2545861 |
|
Hyoscine butylbromide |
Inj 20 mg, 1 ml ampoule; 5 ampoule pack |
$6.35 |
$1.91 |
Spazmol (Devatis) |
1 July 2023 |
1 December 2023 |
Buscopan (Sanofi-Aventi) Buscopan S29 (Sanofi-Aventi) |
|
Ondansetron |
Tab disp 4 mg; 10 tablet blister pack |
$0.76 |
$0.56 |
Periset ODT (Miro) |
1 October 2023 |
1 March 2024 |
Ondansetron ODT-DRLA (Dr Reddy’s) |
|
Ondansetron |
Tab disp 8 mg; 10 tablet blister pack |
$1.13 |
$0.90 |
Periset ODT (Miro) |
1 October 2023 |
1 March 2024 |
Ondansetron ODT-DRLA (Dr Reddy’s) |
|
Rosuvastatin |
Tab 5 mg; 30 tablet bottle pack |
$1.70 |
$1.29 |
Rosuvastatin Viatris (Viatris) |
1 July 2023 |
1 December 2023 |
Rosuvastatin Viatris (Viatris) Pharmacode 2616742 |
|
Rosuvastatin |
Tab 10 mg; 30 tablet bottle pack |
$2.42 |
$1.69 |
Rosuvastatin Viatris (Viatris) |
1 July 2023 |
1 December 2023 |
Rosuvastatin Viatris (Viatris) Pharmacode 2616750 |
|
Rosuvastatin |
Tab 20 mg; 30 tablet bottle pack |
$3.92 |
$2.71 |
Rosuvastatin Viatris (Viatris) |
1 July 2023 |
1 December 2023 |
Rosuvastatin Viatris (Viatris) Pharmacode 2616769 |
|
Rosuvastatin |
Tab 40 mg; 30 tablet bottle pack |
$5.28 |
$4.55 |
Rosuvastatin Viatris (Viatris) |
1 July 2023 |
1 December 2023 |
Rosuvastatin Viatris (Viatris) Pharmacode 2616777 |
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule
3. Tenders awarded to Pharmaceuticals where no other brand is listed
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
DV |
Date of price change |
Principal Supply date |
|---|---|---|---|---|---|---|---|
|
Docetaxel2 |
Inj 10 mg per ml, 8 ml vial; 1 vial pack |
$46.89 |
$24.91 |
DBL Docetaxel (Pfizer) |
5% |
1 July 2023 |
1 December 2023 |
|
Melphalan3 |
Inj 50 mg vial; 1 vial pack |
$65.00 |
$48.25 |
Melpha (Luminarie) |
5% |
1 July 2023 |
1 December 2023 |
|
Naltrexone hydrochloride4 |
Tab 50 mg; 30 tablet blister pack |
$133.33 |
$83.33 |
Naltracord (Teva) |
5% |
1 July 2023 |
1 December 2023 |
|
2The price and subsidy of docetaxel (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 July 2023. The subsidy of docetaxl (Baxter) inj will also be amended from $0.65 per 1 mg to $0.35 mg per 1 mg from 1 July 2023 3The price and subsidy of melphalan (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 July 2023. 4This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 4, clause 2.3 (c)(ii) of the 2022/23 Invitation To Tender. |
|||||||
4. Tenders awarded to pharmaceuticals where at least one other brand is listed
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV limit |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Entecavir |
Tab 0.5 mg; 30 tablet blister pack |
$52.00 |
$12.04 |
Entecavir (Rex) (Rex Medical) |
5% |
1 October 2023 |
1 March 2024 |
Entecavir Sandoz (Sandoz) |
|
Ezetimibe |
Tab 10 mg; 30 tablet bottle pack |
$1.95 |
$1.76 |
Ezetimibe Sandoz (Sandoz) |
5% |
1 July 2023 |
1 December 2023 |
Ezetimibe Sandoz (Sandoz) Pharmacode 2545861 |
|
Hyoscine butylbromide |
Inj 20 mg, 1 ml ampoule; 5 ampoule pack |
$6.35 |
$1.91 |
Spazmol (Devatis) |
5% |
1 July 2023 |
1 December 2023 |
Buscopan (Sanofi-Aventi) |
|
Ondansetron |
Tab dispersible 4 mg; 10 tablet blister pack |
$0.76 |
$0.56 |
Periset ODT (Miro) |
5% |
1 October 2023 |
1 March 2024 |
Ondansetron ODT-DRLA (Dr Redddy’s) |
|
Ondansetron |
Tab dispersible 8 mg; 10 tablet blister pack |
$1.13 |
$0.90 |
Periset ODT (Miro) |
5% |
1 October 2023 |
1 March 2024 |
Ondansetron ODT-DRLA (Dr Reddy’s) |
|
Rosuvastatin |
Tab 5 mg; 30 tablet bottle pack |
$1.70 |
$1.29 |
Rosuvastatin Viatris (Viatris) |
5% |
1 July 2023 |
1 December 2023 |
Rosuvastatin Viatris (Viatris) Pharmacode 2616742 |
|
Rosuvastatin |
Tab 10 mg; 30 tablet bottle pack |
$2.42 |
$1.69 |
Rosuvastatin Viatris (Viatris) |
5% |
1 July 2023 |
1 December 2023 |
Rosuvastatin Viatris (Viatris) Pharmacode 2616750 |
|
Rosuvastatin |
Tab 20 mg; 30 tablet bottle pack |
$3.92 |
$2.71 |
Rosuvastatin Viatris (Viatris) |
5% |
1 July 2023 |
1 December 2023 |
Rosuvastatin Viatris (Viatris) Pharmacode 2616769 |
|
Rosuvastatin |
Tab 40 mg; 30 tablet bottle pack |
$5.28 |
$4.55 |
Rosuvastatin Viatris (Viatris) |
5% |
1 July 2023 |
1 December 2023 |
Rosuvastatin Viatris (Viatris) Pharmacode 2616777 |
Tender declines - Products where no tender is to be awarded for Principal Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2022/23 Invitation to Tender, dated 31 October 2022.
|
Chemical name |
Line item |
|---|---|
|
Ezetimibe (Widened access) |
Tab 10 mg |
|
Capsaicin |
Crm 0.025% |
|
Capsaicin (Current access) |
Crm 0.075% |
|
Capsaicin (Widened access) |
Crm 0.075% |
|
Metyrapone |
Cap 250 mg |
|
Rifaximin |
Tab 200 mg – 550 mg |
|
Vecuronium |
Inj 10 mg |
For products included in the 2020/21, 2021/22 and 2022/2023 Invitation to Tender where no announcement has yet been made, either a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.